Galderma fends off Dr Reddy IPR claims

17-02-2016

Galderma fends off Dr Reddy IPR claims

Tashatuvango / Shutterstock.com

Galderma Laboratories has successfully avoided three inter partes review (IPR) petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.


Foley & Lardner LLP, Dr. Reddy’s Laboratories, Oracea, Galderma Laboratories, inter partes review, IPR

LSIPR